Iron(III)‐tCDTA derivatives as MRI contrast agents: Increased T1 relaxivities at higher magnetic field strength and pH sensing
Sign Up to like & getrecommendations! Published in 2021 at "Magnetic Resonance in Medicine"
DOI: 10.1002/mrm.28664
Abstract: Low molecular weight iron(III) complex‐based contrast agents (IBCA) including iron(III) trans‐cyclohexane diamine tetraacetic acid [Fe(tCDTA)]− could serve as alternatives to gadolinium‐based contrast agents in MRI. In search for IBCA with enhanced properties, we synthesized derivatives… read more here.
Keywords: contrast agents; iron iii; iii tcdta;